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Abstract
A simple, sensitive and cost-effective HPLC-UV bioanalytical method for determina-
tion of lopinavir (LPV) in rat and human plasma was developed and validated. The
plasma sample preparation procedure includes a combination of protein precipitation
using cold acetonitrile and liquid–liquid extraction with n-hexane–ethyl acetate (7:3,
v/v). A good chromatographic separation was achieved with a Phenomenex Gemini
column (C18, 150mm × 2.0 mm, 5 μm) at 40C with gradient elution, at 211 nm. Cali-
bration curves were linear in the range 10–10,000 ng/mL, with a lower limit of quan-
tification of 10 ng/mL using 100 μL of plasma. The accuracy and precision in all
validation experiments were within the criteria range set by the guidelines of the
Food and Drug Administration. This method was successfully applied to a preliminary
pharmacokinetic study in rats following an intravenous bolus administration of LPV.
Moreover, the method was subsequently fully validated for human plasma, allowing
its use in therapeutic drug monitoring (TDM). In conclusion, this novel, simple and
cost-efficient bioanalytical method for determination of LPV is useful for pharmaco-
kinetic and drug delivery studies in rats, as well as TDM in human patients.
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1 | INTRODUCTION
Lopinavir (LPV) is an HIV (human immunodeficiency virus) protease
inhibitor (PI) coadministered with a low dose of ritonavir (RTV)
under the brand name Kaletra (LPV/r) as part of antiretroviral
treatment (ART) in people affected by HIV. The combination
was approved by the U.S. Food and Drug Administration (FDA)
two decades ago (Oldfield & Plosker, 2006). Since 2006, the
World Health Organization (WHO) guidelines have consistently
recommended LPV/r as one of PIs in second-line regimens (World
HealthOrganization, 2006). In the latestWHO guidelines (2019), LPV/r
is still recommended as the preferred PI therapy for second-line ART
regimen, alternative first-line ART regimen in children and in special
circumstances in neonates (World Health Organization, 2019).
Most recently, due to the global outbreak of the severe acute respi-
ratory syndrome coronavirus 2 (SARS-CoV-2) infection leading to
COVID-19 disease, LPV/r is being considered as one of the poten-
tial candidates, with multiple clinical trials initiated to test its
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efficacy (ChiCTR2000029496, ChiCTR2000029539, NCT04307693,
NCT04252885).
By the end of 2018, an estimated 37.9 million people globally
were living with HIV (including 1.7 million children). Moreover, 1.7
million in total were newly infected with HIV (including 0.16 million
children) in 2018 alone (UNAIDS, 2019). However, only US$ 19 billion
was available for HIV/AIDS (acquired immunodeficiency syndrome)
response in low- and middle-income countries (end 2018), about US$
1 billion less than that was available in 2017 (US$ 19.9 billion;
UNAIDS, 2019). The relatively low funding, as well as the stagnation
in the rate of new HIV infections in recent years, is a challenge for
efficient and rapid diagnostics and monitoring for people in resource-
limited settings. More than 70% of patients from low- to middle-
income countries undergoing second-line regimens are receiving
LPV/r (World Health Organization, 2018). Therefore, cost-effective
and sensitive bioanalytical methods for therapeutic drug monitoring
(TDM) of LPV are needed, mostly in developing countries. To be rele-
vant for TDM, these methods need to cover the range of clinically rel-
evant plasma concentrations of LPV in HIV-infected individuals
receiving LPV/r regimen (Eron et al., 2004; Ribera et al., 2004). In
addition, the bitter taste reported with various formulations of LPV/r
combination (Phelps & Rakhmanina, 2011) is likely to affect adher-
ence, which increases the need for TDM in HIV-infected children.
Moreover, application of the new bioanalytical method for the preclin-
ical studies in rats also allows more cost-effective preclinical research,
and, importantly, inclusion of resource-limited developing countries in
the research activities.
To date, a large number of bioanalytical methods were devel-
oped for the determination of LPV with other antiretroviral drugs in
plasma using HPLC with UV detection (Faux, Venisse, Olivier, &
Bouquet, 2001; Justesen, Pedersen, & Klitgaard, 2003; Notari
et al., 2006; Poirier, Robidou, & Jaillon, 2005; Ray, Pang, &
Carey, 2002; Rezk, Tidwell, & Kashuba, 2004; Weller, Brundage,
Balfour, & Vezina, 2007) or LC–tandem mass spectrometry (LC–
MS/MS; Else et al., 2010; Estrela, Ribeiro, Seixas, & Suarez-Kurtz,-
2008; Martin et al., 2009; Temghare, Shetye, & Joshi, 2009).
However, previously reported bioanalytical methods for determina-
tion of LPV utilizing the HPLC-UV methodology are not sensitive
enough when low-volume samples are used (Vats, Murthy, &
Ravi, 2011). By contrast, the LC–MS/MS methodology does provide
sufficient sensitivity, but is too expensive for efficient TDM or pre-
clinical research in resource-limited countries. One published
bioanalytical method achieved good sensitivity with lower limit of
quantification (LLOQ) of 5 ng/mL using HPLC-UV for determination
of LPV (Notari et al., 2006), while another published method utilized
LC–MS/MS to obtain LLOQ as low as 1 ng/mL (Estrela et al., 2008).
However, a relatively high volume of plasma (600 and 200 μL,
respectively) was needed to achieve these high sensitivities in both
methods. The relatively high volume of plasma on the scale of 600 μ
L is problematic for TDM in children, while the scale of 200 μL is
still quite high for pharmacokinetic studies in small laboratory ani-
mals, such as rats or mice. In addition, due to the fact that safe han-
dling of HIV-positive biological samples in clinics is a priority, drug
stability in heat-inactivated conditions [56C, 30 mins (Tjøtta,
Hungnes, & Grinde, 1991)] has been mostly validated in published
methods (Avolio et al., 2011; Egge-Jacobsen et al., 2004; Else
et al., 2010; Poirier et al., 2005). As a result, the proposed validation
of our bioanalytical method also covers drug stability in heat-
inactivated conditions, as well as a full validation recommended by
FDA guidelines (Food and Drug Administration, 2018).
Therefore, in this work, a simple, sensitive, cost-efficient and
low sample volume bioanalytical method for determination of LPV
in rat plasma was developed and fully validated using HPLC with
UV detection. This method was successfully implemented in a phar-
macokinetic study following intravenous administration of LPV in
rats. Moreover, the method has been fully validated for human
plasma to provide a cost-effective option for clinical research
and TDM.
2 | MATERIAL AND METHODS
2.1 | Chemicals and reagents
LPV (CAS: 192725–17-0) was purchased from Fisher Scientific
(Leicestershire, UK), RTV (CAS: 155213–67-5) from Sigma-Aldrich
(Gillingham, UK) and cannabidiol (CAS: 13956–29-1) from THC
Pharm (Germany). HPLC-grade ethyl acetate, n-hexane and acetoni-
trile were purchased from Fisher Scientific (Leicestershire, UK).
HPLC-grade water was obtained from PURELAB Ultra system (ELGA
LabWater, UK). Rat plasma was purchased from Sera Laboratories
(West Sussex, UK) and human plasma from TCS Bioscience
(Buckingham, UK). All other research reagents used were of HPLC
grade or higher.
2.2 | Chromatographic system
The HPLC-UV system consisted of a Waters Alliance 2695 separa-
tions module equipped with a Waters 996 photodiode array detector.
Separation was accomplished at 40C using an analytical C18 Gemini
column (150mm × 2.0mm internal diameter) with a particle size of 5
μm, coupled with a guard column (2mm× 4mm) with a particle size of
3 μm (Phenomenex, Macclesfield, UK). All compounds were monitored
at 211 nm. The final composition of the mobile phase consisted of
TABLE 1 Gradient conditions
Time (min) Flow (mL/min) Water (%) Acetonitrile (%)
0 0.30 50 50
10 0.30 50 50
11 0.30 30 70
19 0.30 30 70
20 0.30 50 50
25 0.30 50 50
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water and acetonitrile mixture with gradient program (Table 1) at the
flow rate of 0.3 mL/min. The injection volume was 40 μL. The temper-
ature of autosampler was maintained at 4C. Empower 2 software
was used for data acquisition and analysis throughout the method
development and validation.
2.3 | Calibration curves and quality control samples
Stock standard solutions of LPV and internal standard (IS) cannabidiol
were prepared by dissolving 10mg of each compound in 1.0 mL of
acetonitrile (10mg/mL final concentration) and stored at −20C.
Working standard solutions of LPV for calibration curves were diluted
from stock standard solution using acetonitrile to yield concentrations
of 0.1, 0.2, 0.5, 1, 5, 10, 50 and 100 μg/mL. Working standard
solution of IS was prepared in a same procedure to yield a concentra-
tion of 10 μg/mL. Calibration curves were established by spiking
100 μL of rat plasma with 10 μL of corresponding working standard
solutions of LPV to yield concentrations of 10, 20, 50, 100,
500, 1000, 5000 and 10,000 ng/mL.
Working standard solutions of LPV for quality control
(QC) samples were independently prepared in acetonitrile at concen-
trations of 0.1, 0.25, 4 and 80 μg/mL. A volume of 10 μL of working
standard solutions was spiked into 100 μL rat plasma to obtain LLOQ,
low quality control (LQC), medium quality control (MQC) and high
quality control (HQC) samples at concentrations of 10, 25, 400 and
8000 ng/mL, respectively.
2.4 | Sample preparation procedure
All samples went through the same process of combination of pro-
tein precipitation and liquid–liquid extraction for HPLC-UV analysis.
IS (10 μL) was added to 100 μL of rat plasma in a 16mm × 150
mm glass tube. Then, 300 μL of cold acetonitrile (−20C) was
added, followed by vortex mixing for 1min. HPLC-grade water
(300 μL) was then added and vortex mixed again for 1min (Zgair
et al., 2015). A volume of 3mL of extraction solvent, consisting of
a mixture n-hexane and ethyl estate (7:3, v/v), was added and the
samples were vortex mixed for 3 min. Following centrifugation
(1160g, 10C, 10min), the upper organic layers were transferred to
fresh tubes using a Pasteur pipette and evaporated under nitrogen
at 40C (Techne DRI-Block type DB-3D, Cambridge, UK). Dry resi-
dues were reconstituted in 100 μL of mobile phase (50% acetoni-
trile in water), vortex mixed for 10min and then transferred to
HPLC vials.
2.5 | Method validation
A full validation of the new method was carried out in accordance
with the FDA guidance for Bioanalytical Method Validation (Food and
Drug Administration, 2018).
2.5.1 | Selectivity
The selectivity of this new HPLC-UV analytical method was assessed
by comparing the chromatograms of pooled blank rat plasma samples
with the chromatograms of six replicates of plasma samples spiked
with LPV at LLOQ standard solution. The selectivity was further
assessed in the samples from intravenous bolus administration of LPV
to rats.
2.5.2 | Accuracy and Precision
Accuracy was expressed as relative error (RE) and precision as relative
standard deviation (RSD). The intra-day accuracy and precision were
validated using six-replicate analysis of QC (LQC, MQC and HQC) and
LLOQ samples on the same day. The inter-day accuracy and precision
were also assessed at the same concentrations on 6 separate days.
Based on FDA guidelines, the mean value of accuracy should be
within ±15% of the nominal concentration except for the LLOQ which
should be within ±20%. The percentage of precision should not
exceed 15% except for the LLOQ in which 20% deviation is accepted
(Food and Drug Administration, 2018).
2.5.3 | Sensitivity
The LLOQ was defined as the lowest tested concentration of the drug
with the RE within ±20% and RSD ≤ 20%, for both intra- and inter-
day runs (Food and Drug Administration, 2018).
2.5.4 | Linearity
Calibration curves (the ratio of LPV peak to IS peak area versus nomi-
nal concentration) were fitted by least squares linear regression analy-
sis using a weighted factor (1/X). To validate linearity, correlation
coefficient (r2) should be over 0.99 and accuracy should be within
±15% (expect for LLOQ in which variability within ±20% is allowed;
Food and Drug Administration, 2018).
2.5.5 | Recovery
Percentage (%) recovery for LPV was determined by comparing the
chromatographic peak areas of QC samples following extraction with
peak areas obtained from equivalent levels dissolved directly in recon-
stitution solvent. The recovery of IS was determined in the same way.
2.5.6 | Stability
Stability assays were designed to mimic the likely conditions in
which samples will be stored, transferred, processed and analyzed.
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QC Samples (LQC, MQC and HQC) were prepared by spiking LPV
solution into blank rat plasma. Stability during thermization (heat-
inactivation of HIV) was validated by incubating six replicates of
QC samples (LQC, MQC and HQC) at 56C for 30min (Tjøtta
et al., 1991). Freeze–thaw stability was assessed by three cycles of
freezing the samples at −80C for 24 hr and then thawing at room
temperature. Benchtop stability was assessed for 6 hr at room tem-
perature. Short-term stability was studied for 24 hr at −20C, and
long-term stability for 4 and 8 weeks at −80C. Autosampler stabil-
ity was also assessed by storing six replicates of processed QC
samples (LQC, MQC and HQC) at 4C for 24 hr. Working standard
solutions (0.25, 4 and 80 μg/mL) were prepared and stored at
room temperature for 6 hr, and then used to prepare six replicates
of QC samples (LQC, MQC and HQC) for assessing stock solution
stability. Analytes were considered to be stable in plasma
when accuracy and precision were within acceptable limits
(RE within ±15% and RSD ≤ 15%, respectively; Food and Drug
Administration, 2018).
2.6 | Method application and validation in human
plasma
The method of sample preparation procedure, chromatography condi-
tions and method validation (excluding long-term stability conditions)
of LPV in human plasma were identical to those reported for rat
plasma above.
2.7 | Pharmacokinetic study in rats
Animal welfare and all experimental procedures were reviewed and
approved by the University of Nottingham Ethical Review Commit-
tee under the Animals [Scientific Procedures] Act 1986. Three male
Sprague Dawley rats (300–330 g) were obtained from Charles River
Laboratories (UK) and housed at Bio Support Unit, University of
Nottingham. They were kept in an environmentally controlled room
(12:12-hr light–dark cycle) with free access to food and water for
at least six days before starting experiment. Surgical anesthesia
was induced by inhalation of 2.5% isoflurane in oxygen (World
Precision Instruments, 2019). Cannulation surgery was performed
by implantation of silastic-polyethylene (PE-50) tubing into the
right external jugular vein as previously described (Lee et al., 2017;
Thrivikraman, Huot, & Plotsky, 2002; Zgair et al., 2015). Rats
were allowed to recover for two nights before pharmacokinetic
experiment.
A solution of LPV was prepared at a concentration of 4mg/mL
in a mixture of propylene glycol–sterile water–ethanol (70:20:10,
v/v/v). The drug was administered as an intravenous bolus through
the jugular vein cannula at a dose of 4 mg/kg. Blood samples (0.2
mL) were withdrawn from catheter before administration, and
at 5, 15, 30, 60, 120, 180, 240 and 360min following administra-
tion. Plasma samples were separated immediately by centrifugation
(3000g, 5 min) and stored at −80C until analysis. Pharmacokinetic
parameters were obtained by non-compartment analysis using
Phoenix WinNonlin 6.3 software (Pharsight, Mountain View,
CA, USA).
3 | RESULTS AND DISCUSSION
3.1 | Method development
Because LPV is not a highly lipophilic compound (Log P = 1.7, experi-
mental result; Ford, Khoo, & Back, 2004), n-hexane (non-polar
organic solvent) was not efficient in extraction of LPV from
plasma (the absolute recovery was zero). Adding 30% ethyl acetate
to n-hexane enhanced extraction efficiency dramatically and the
mixture of n-hexane–ethyl acetate 7:3 (v/v) was selected as the
optimum extraction solvent. In addition to the extracting solvent
composition, the duration of the extraction was also optimized in
this assay. It was observed that LPV was extracted very rapidly
(within 3-min vortex mixing) into the organic phase during the
liquid–liquid extraction procedure. Further increase in the duration
of the extraction did not improve the recovery. Similar to a previ-
ously reported work from our group for bioanalysis of
phytocannabinoids, addition of water following plasma protein pre-
cipitation before the liquid–liquid extraction improved the extraction
efficiency and the chromatography baseline (Zgair et al., 2015).
Cannabidiol was selected as an IS because it had similar extraction
procedure and efficiency to LPV in our previous work (Zgair
et al., 2015), as well as longer retention time than LPV in chroma-
tography conditions developed in this work.
A simple buffer-free gradient mobile phase, starting from a mix-
ture of acetonitrile–water (50:50, v/v), gave optimal separation of LPV
from background peaks. A higher percentage of acetonitrile was
gradually blended in mobile phase to elute IS (Table 1). Both LPV and
IS were monitored at 211 nm, as LPV had the highest UV absorbance
and chromatography baseline was clean at LPV retention time at
this wavelength.
3.2 | Method validation for rat plasma
3.2.1 | Selectivity
This analytical method showed good selectivity and the peak of LPV
was well-separated from endogenous peaks in blank rat plasma
(Figure 1a–c), indicating minimum matrix effect and absence of
carryover. In addition, this method was applied to evaluate drug
concentrations in rat plasma following intravenous administration, and
in these samples there was also no interference between the LPV, IS
and endogenous peaks (Figure 1d). Therefore, this method is
selective for determination of LPV in rat plasma and suitable for
pharmacokinetic experiments in these species.
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3.2.2 | Accuracy and precision
Samples were assessed at four different concentrations in six repli-
cates to evaluate accuracy (RE) and precision (RSD), respectively.
Results for intra- and inter-day validation of LLOQ and QC samples
are listed in Table 2. For accuracy and precision validation, the mean
values of all QC samples (LQC, MQC and HQC) were within accept-
able range (RE within ±15% and RSD ≤ 15%). For the LLOQ, RE was
within ±20% and RSD ≤ 20%. These results indicate that this analytical
method is suitable for determination of LPV levels in rat plasma in an
accurate and precise manner (Food and Drug Administration, 2018).
3.2.3 | Sensitivity and linearity
In this method, 10 ng/mL was determined as LLOQ, because intra-
and inter-day accuracy and precision validations for LLOQ samples
were within acceptable range (RE within ±20% and RSD ≤ 20%;
Table 2). The method was linear for LPV with correlation coefficient
(r2) greater than 0.99 in all calibration curves in the range of
10–10,000 ng/mL, indicating dilution integrity in this range under the
conditions of this assay. To note, a low volume of plasma (100 μL) was
needed to achieve the LLOQ of 10 ng/mL which makes this assay suf-
ficiently sensitive to perform preclinical pharmacokinetic studies in
small laboratory animals or other situations when sample volume is
limited. In previously reported studies, some bioanalytical methods
achieved better sensitivities (LLOQ < 10 ng/mL), but required higher
volume of plasma and/or more expensive analytic equipment such as
an LC–MS/MS system (Estrela et al., 2008; Notari et al., 2006).
3.2.4 | Recovery
Mean absolute recoveries of LPV in LQC, MQC and HQC samples
were 88.7% ± 2.1%, 96.5% ± 1.0% and 96.4% ± 2.1%, respectively
(mean ± SD, n = 6). The absolute recovery of IS was 70.6% ± 2.5%
(mean ± SD, n = 3). The optimized liquid–liquid extraction step con-
tributed to excellent recovery of LPV from rat plasma, thereby achiev-
ing good sensitivity of this method.
3.2.5 | Stability
The results of all stability experiments are presented in Table 3. All
QC samples (LQC, MQC and HQC) were considered to be stable
under different realistic storage conditions, with the values of accu-
racy (RE) and precision (RSD) in the acceptable range (RE within
±15%, RSD ≤ 15%). Very limited LPV stability data in rat plasma have
been reported in previous studies and only included freeze–thaw,
short-term and autosampler stability experiments (Vats et al., 2011).
To the best of our knowledge, this is the first report that covers full
validation and stability of LPV in rat plasma according to FDA guide-
lines (Food and Drug Administration, 2018). Moreover, the stability of
LPV in rat plasma was originally validated at heat-inactivated condi-
tions only (Tjøtta et al., 1991).
F IGURE 1 Representative chromatograms of (a) rat plasma blank
sample; (b) rat plasma spiked with 1000 ng/mL LPV; (c) rat plasma
spiked with 8000 ng/mL LPV and (d) plasma obtained at 5 minutes
following intravenous administration of LPV in rat (4 mg/kg). All
chromatograms are observed at λ = 211 nm. IS, internal standard; LPV,
lopinavir
TABLE 2 Intra- and inter-day validation results for determination
of lopinavir in rat plasma
Nominal
concentration
levels
Intra-day (n = 6) Inter-day (n = 6)
Accuracy
(RE, %)
Precision
(RSD, %)
Accuracy
(RE, %)
Precision
(RSD, %)
LLOQ (10
ng/mL)
5.59 15.80 15.36 2.93
LQC (25
ng/mL)
−7.02 1.64 −2.09 10.90
MQC (400
ng/mL)
−5.67 2.26 −2.91 8.61
HQC (8000
ng/mL)
−1.78 3.69 1.22 5.68
HQC, high quality control; LLOQ, lower limit of quantification; LQC, low
quality control; MQC, medium quality control; RE, relative error; RSD, rela-
tive standard deviation.
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3.3 | Pharmacokinetic study in rats
The developed bioanalytical method was applied to a preclinical phar-
macokinetic study in rats following single intravenous bolus adminis-
tration. The individual plasma concentration–time profiles of LPV in
three rats are shown in Figure 2, and mean plasma pharmacokinetic
parameters obtained using non-compartmental analysis are presented
in Table 4. Limited number of preclinical pharmacokinetic studies fol-
lowing single intravenous bolus of LPV in rats have been reported
(Kumar et al., 2004; Vats et al., 2011). The elimination t1/2 (0.49 ±
0.01 hr) obtained in this study is shorter than the t1/2 previously
reported (0.82 ± 0.03 hr) using the HPLC-UV method for the detection
of LPV (Vats et al., 2011). The lower sensitivity of the previously
reported method (LLOQ= 250 ng/mL) limited sampling up to 3 hr,
which resulted in sampling duration of less than four times the elimi-
nation t1/2. However, to better characterize a pharmacokinetic profile,
sampling should preferably be four to five times the elimination t1/2
(Dunnington et al., 2018). In the current study, a high sensitivity
(LLOQ = 10 ng/mL) allows sampling up to 4 hr (more than eight times
the elimination t1/2), thereby accurately characterizing the pharmaco-
kinetic profile of LPV. Kumar et al. (2004) reported a significantly lon-
ger elimination t1/2 (mean value of 2.07 hr) compared with other
studies. This prolonged elimination t1/2 is probably a result of the ana-
lytical assay which utilized LPV. This trend has been previously
observed for other compounds in which radioactivity-based
bioanalytical methods were used (Isin, Elmore, Nilsson, Thompson, &
Weidolf, 2012).
3.4 | Assessment and validation of the developed
bioanalytical method in human plasma for clinical
therapeutic drug monitoring
Following the development and validation of the bioanalytical
method for determination of LPV in rat plasma, the suitability of this
method for clinical research and clinical TDM of HIV-infected
patients receiving LPV/r therapy was assessed. A routine TDM plays
an important role in ART to assist clinicians in assessing adherence
and optimizing the regimens for HIV-infected patients, and therefore
to reduce the risks of insufficient therapeutic response, drug resis-
tance or toxicity. This is particularly important in relation to PIs, as
the pharmacokinetics of PIs is known to have high inter-individual
variability (Barry et al., 1998; Regazzi et al., 1999; van der Leur,
Burger, Porte, & Koopmans, 2006). Very high concentration of LPV
can lead to adverse effects such as hyperlipidemia (Gutiérrez
et al., 2003; Limsreng, Marcy, Ly, Ouk, & Chanroeurn, 2016; Montes
et al., 2005) and gastrointestinal disorders (Boffito et al., 2005; Hill &
Balkin, 2009), whereas concentration below the therapeutic window
would lead to therapeutic failure and drug resistance (Breilh,
Pellegrin, Berthoin, & Xuereb, 2004; Masquelier et al., 2002). More-
over, the poor palatability of LPV/r liquid formulations (Phelps &
Rakhmanina, 2011) increases the risk of suboptimal antiretroviral
efficiency in children due to poor adherence. Therefore, this cost-
effective and sensitive bioanalytical method, involving low volume
samples of plasma, could be useful for monitoring plasma concentra-
tions of LPV in adults and children in both developed and resource-
limited countries.
The same calibration curve range (10–10,000 ng/mL) was used in
the assessment of the newly developed bioanalytical method for
human plasma, because the mean Cmax, Cmin and Ctrough of LPV were
reported to be within this range during LPV/r regimen (400/100mg b.
i.d.) in HIV-infected adults (Eron et al., 2004; Ribera et al., 2004). The
reported mean Ctrough levels of LPV following LPV/r regimens based
on body weight in HIV-infected children were also within this range
(Puthanakit et al., 2010). The same sample preparation procedure and
chromatography conditions used for rat plasma were also applied to
human plasma. Good selectivity was observed by comparison of chro-
matograms between LPV/RTV-spiked samples and blank human
plasma samples (Figure 3). Intra- and inter-day accuracy (RE) and pre-
cision (RSD) were assessed using six spiked human plasma samples at
four different concentrations (LLOQ and QCs) for LPV (Table 5). The
same sensitivity (LLOQ = 10 ng/mL) and linearity range (r2 > 0.99) as
for rat plasma were achieved when the method was applied to human
plasma. The extraction recovery of human plasma LQC, MQC and
F IGURE 2 Plasma concentration–time profiles of LPV in rats
following intravenous administration at 4mg/kg (n = 3). LPV, lopinavir
TABLE 4 Pharmacokinetic parameters of lopinavir following a
single intravenous administration of 4mg/kg to rats (n = 3)
Parameters Mean SD
AUCinf (hng/mL) 2709 371
AUC0!t (hng/mL) 2699 372
C0 (ng/mL) 5992 2033
t1/2 (h) 0.49 0.01
Vss (mL/kg) 1053 271
CL (mL/h/kg) 1495 200
AUC0!t, area under the curve from time zero to the last sampling time
point; AUCinf, area under the curve from time zero to infinity; C0, concen-
tration extrapolated to time zero; CL, clearance; SD, standard deviation;
t1/2, elimination half-life; Vss, volume of distribution at steady state.
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HQC samples were 94.3% ± 4.9%, 99.6% ± 2.2% and 99.5% ± 3.5%,
respectively (mean ± SD, n = 6).
The stability of LPV at three concentrations (QCs) in human
plasma under different realistic storage conditions is shown inTable 6.
The LPV was stable in human plasma samples under all tested condi-
tions, because the values of RE and RSD are within acceptable range
(RE within ±15%, RSD ≤ 15%; Food and Drug Administration, 2018).
The heat-inactivation stability has demonstrated that the samples are
stable during the patient plasma HIV inactivation procedure prior to
sample preparation. The benchtop stability and stock solution stabil-
ity show that samples and stock solutions are stable during the sam-
ple preparation procedure. The processed samples are also stable at
4C for 24 hr, mimicking the condition in autosampler. Freeze–thaw
stability indicated that samples are stable after undergoing three
cycles of freeze and thaw, which should allow TDM even after the
samples have been previously used for other tests, such as viral load
monitoring. Plasma samples are also stable under short-term storage
conditions with the acceptable values of RE and RSD. Therefore, a
low plasma volume, good extraction efficiency, high sensitivity and
good stability in human plasma at different storage situations make
this versatile and robust bioanalytical method suitable for clinical
research and clinical TDM of HIV-infected adult and pediatric
patients. This new method of determination of LPV using HPLC-UV
detection maintains similar sensitivity to that previously achieved by
the LC–MS/MS methodology (Estrela et al., 2008), and requires
much lower volume of plasma compared with the previously
reported HPLC-UV method (Notari et al., 2006). Importantly,
the excellent cost-efficacy of this method compared with the
much more expensive LC–MS/MS methodology allows TDM and
clinical research activity in resources-limited countries in the devel-
oping world.
F IGURE 3 Representative chromatograms of (a) blank human
plasma; (b) and (c) human plasma spiked with 5000 ng/mL of LPV and
5000 ng/mL of RTV, respectively; (d) human plasma sample spiked
with 5000 ng/mL of LPV and RTV simultaneously. All chromatograms
are observed at λ = 211 nm. IS, internal standard; LPV, lopinavir; RTV,
ritonavir
TABLE 5 Intra- and inter-day validation results for determination
of lopinavir in human plasma
Nominal
concentration
levels
Intra-day (n = 6) Inter-day (n = 6)
Accuracy
(RE, %)
Precision
(RSD, %)
Accuracy
(RE, %)
Precision
(RSD, %)
LLOQ (10
ng/mL)
5.61 5.60 6.53 10.44
LQC (25
ng/mL)
3.54 4.52 2.11 5.20
MQC (400
ng/mL)
−1.79 4.35 −1.92 2.77
HQC (8000
ng/mL)
−5.57 2.95 2.40 3.56
HQC, high quality control; LLOQ, lower limit of quantification; LQC, low
quality control; MQC, medium quality control; RE, relative error; RSD, rela-
tive standard deviation.
TABLE 6 Stability results of lopinavir in human plasma under various storage conditions (n = 6)
Concentration
levels
Inactivation
stability (56C,
30min)
Benchtop
stability (25C, 6
hr)
Stock solution
stability (25C, 6
hr)
Autosampler
stability (4C, 24
hr)
Short-term
stability (−20C,
24 hr)
Freeze–thaw
stability (−80C,
3 cycles)
RE
(%)
RSD
(%)
RE
(%)
RSD
(%)
RE
(%)
RSD
(%)
RE
(%)
RSD
(%) RE (%)
RSD
(%)
RE
(%)
RSD
(%)
LQC (25 ng/mL) −1.69 5.78 −7.72 2.73 −3.71 6.46 7.43 4.87 −10.10 4.39 7.50 4.45
MQC (400 ng/mL) −2.14 5.28 −3.27 3.12 −5.19 4.21 −7.82 3.76 7.04 3.56 4.28 3.39
HQC (8000 ng/mL) 9.80 3.06 12.27 1.91 2.63 5.59 −2.05 4.64 8.04 4.38 6.29 4.88
HQC, high quality control; LQC, low quality control; MQC, medium quality control; RE, relative error; RSD, relative standard deviation.
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4 | CONCLUSION
A simple, sensitive and cost-efficient HPLC-UV method for the deter-
mination of LPV in rat plasma was developed and fully validated. This
assay achieved higher sensitivity using lower volume of plasma com-
pared with previously reported HPLC-UV methods. This method will
allow preclinical pharmacokinetic and drug delivery studies in rats in
the developed and developing countries in a cost-efficient and reliable
manner. Moreover, the newly developed bioanalytical method was
applied and validated for human plasma with similar good selectivity,
sensitivity, linearity and stability under different storage conditions.
Therefore, this method can be used for clinical research and clinical
TDM of HIV-infected and potentially SARS-CoV-2-infected patients
undergoing LPV/r treatment in a cost-effective manner in the
resource-rich and resource-limited settings.
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